Do the new data from the PCPT “change the game” when it comes to PSA screening?

So, with the new, 15-year survival data from the Prostate Cancer Prevention Trial (PCPT) published earlier this week (as discussed in a prior post), a key question for many is “Do these data significantly change the rationale for or against widespread screening for risk of prostate cancer?” … READ MORE …

New, six-point statement about PSA testing issued at PCWC

According to a report on the Bloomberg.com web site, attendees meeting at the Prostate Cancer World Congress (PCWC) in Melbourne, Australia have issued a new, six-point consensus statement about the use of the PSA test in the initial detection of prostate cancer. … READ MORE …

Decision aids, PSA-based screening, and male decision-making

According to a newly published study in JAMA Internal Medicine, web-based and print-based decision aids do help men to resolve their own internal conflicts about whether or not to get PSA tests for risk of prostate cancer … READ MORE …

New data from the Rotterdam section of the ERSPC: we need better tools

New follow-up data from the Rotterdam section of the European Randomized Study of Screening for Prostate Cancer (ERSPC) trial at a median of 12.8 years suggest that the overall, absolute, prostate cancer-specific mortality rate was 1.8 per 1,000 men randomized or 0.18 percent. … READ MORE …

Risk for prostate cancer once screening ended (from the Göteborg cohort)

Many readers will want to be aware of a new article entitled “Incidence of prostate cancer after termination of screening in a population-based randomised screening trial” that has just been published in European Urology. … READ MORE …

What has your doctor told you about PSA testing?

According to a recent article in the Annals of Family Medicine, about 64 percent of 3,400 men aged between 50 and 74 years of age who participated in a survey conducted in 2010 stated that they had never had a conversation with their doctor about the pros and cons of PSA testing. … READ MORE …

AUA issues new toolkit on prostate cancer screening

In a message sent out to its members this morning, the American Urological Association (AUA) has announced the availability of a new “toolkit” of materials designed to help doctors and patients in discussions about the pros and cons of testing individuals for their risk of prostate cancer. … READ MORE …

More on the screening, biopsy, treatment sequence

There is another iterestinng video discussion available on line on the Medscape web site … this one between Andrew Vickers, DPhil, of Memorial Sloan-Kettering Cancer Center, and Sigrid Carlsson, MD, PhD, of the University of Göteborg in Sweden.
… READ MORE …

Does 120-day mortality after prostate biopsy outweigh any possible benefit of screening?

Back in 2008, Gallina et al. demonstrated that the risk for mortality at 120 days after a prostate biopsy was of the order of 2 deaths per 1,000 prostate biopsies, and historically this is the only population-based study ever to assess this risk. … READ MORE …

Prostate Cancer Roundtable comments on plethora of guidelines on screening

As many readers will be aware, there have been two new sets of guidance about screening for prostate cancer issued in the past few months — the most recent from the American Urological Association just a couple of weeks ago. … READ MORE …

Further comment from the AUA on new PSA screening guidance

The American Urological Association (AUA) sent the following additional message to its members with the past 90 minutes: … READ MORE …

Follow-up on the new AUA guidelines on screening for risk of prostate cancer

One of the things that is most interesting about the new guidelines issued by the AUA last week (see here for original announcement) is that they seem to be gaining reasonably widespread approval — probably because they are actually (and finally) based on actual evidence as opposed to raw opinion. … READ MORE …

AUA issues new guidance on screening for prostate cancer

As of 7 am this morning, the American Urological Association (AUA) has issued a new set of guidelines on screening for prostate cancer. The full text of this set of guidelines is already available on the AUA web site. … READ MORE …

Finnish Prostate Cancer Screening Trial shows very limited impact on mortality after 12 years

According to a recent analysis of data from the Finnish Prostate Cancer Screening Trial (which was the single largest contributor to the data collected in the European Randomized Study of Screening for Prostate Cancer or ERSPC), this Finnish trial showed no statistically significant reduction in mortality at 12 years of follow-up. … READ MORE …

Screening smarter — more supportive PSA data from the Malmö Preventive Project

So a new paper just published in the British Medical Journal offers further evidence that a PSA test offered to men between 45 and 49 years of age can predict lifetime risk for prostate cancer with a significant level of accuracy. … READ MORE …

Follow

Get every new post delivered to your Inbox.

Join 1,074 other followers